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IMPORTANCE Microvascular obstruction commonly affects patients with acute ST-segment
elevationmyocardial infarction (STEMI) and is associated with adverse outcomes.
OBJECTIVE To determine whether a therapeutic strategy involving low-dose intracoronary
fibrinolytic therapy with alteplase infused early after coronary reperfusion will reduce
microvascular obstruction.
DESIGN, SETTING, AND PARTICIPANTS BetweenMarch 17, 2016, and December 21, 2017, 440
patients presenting at 11 hospitals in the United Kingdomwithin 6 hours of STEMI due to a
proximal–mid-vessel occlusion of a major coronary artery were randomized in a 1:1:1
dose-ranging trial design. Patient follow-up to 3months was completed on April 12, 2018.
INTERVENTIONS Participants were randomly assigned to treatment with placebo (n = 151),
alteplase 10mg (n = 144), or alteplase 20mg (n = 145) bymanual infusion over 5 to 10
minutes. The intervention was scheduled to occur early during the primary PCI procedure,
after reperfusion of the infarct-related coronary artery and before stent implant.
MAIN OUTCOMES ANDMEASURES The primary outcomewas the amount ofmicrovascular
obstruction (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic
resonance imaging (MRI) conducted from days 2 through 7 after enrollment. The primary
comparison was the alteplase 20-mg group vs the placebo group; if not significant, the
alteplase 10-mg group vs the placebo group was considered a secondary analysis.
RESULTS Recruitment stopped onDecember 21, 2017, because conditional power for the
primary outcomebased on a prespecified analysis of the first 267 randomized participantswas
less than 30% in both treatment groups (futility criterion). Among the 440patients randomized
(mean age, 60.5 years; 15%women), the primary end pointwas achieved in 396patients (90%),
17 (3.9%)withdrew, and all otherswere followed up to 3months. In the primary analysis, the
meanmicrovascular obstruction did not differ between the 20-mg alteplase and placebo groups
(3.5%vs 2.3%; estimated difference, 1.16%; 95%CI, −0.08% to 2.41%; P = .32) nor in the
analysis of 10-mg alteplase vs placebo groups (2.6%vs 2.3%; estimated difference, 0.29%; 95%
CI, −0.76% to 1.35%; P = .74).Major adverse cardiac events (cardiac death, nonfatalMI,
unplanned hospitalization for heart failure) occurred in 15 patients (10.1%) in the placebo group,
18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase group.
CONCLUSIONS AND RELEVANCE Among patients with acute STEMI presenting within 6 hours
of symptoms, adjunctive low-dose intracoronary alteplase given during the primary
percutaneous intervention did not reducemicrovascular obstruction. The study findings do
not support this treatment.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02257294
JAMA. 2019;321(1):56-68. doi:10.1001/jama.2018.19802
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I
schemic heart disease is the leading cause of disability1
and death2worldwide. Acute coronary thrombosis causes
ST-elevation myocardial infarction (STEMI) and primary
percutaneous coronary intervention (PCI) to emergently
reopen the occluded coronary artery and secure vessel pat-
ency with a stent is the evidence-based standard of care.3 Pri-
mary PCI is routinely successful and normalized coronary
blood flow is typically achieved in 91% of patients.4However,
failed microvascular reperfusion has been estimated to occur
in 45% of all treated patients.5,6 This complication, described
as microvascular obstruction, is independently predictive of
an unfavorable cardiac prognosis.7 During primary PCI, distal
embolization of thrombus from the lumen of the main coro-
nary artery and microvascular thrombosis,8-12 notably of
fibrin-rich microthrombi,9,12 contribute to microvascular
obstruction. Clinicians lack the therapeutic tools to treat
microvascular obstruction.3
Fibrinolytic therapy is alsoaneffective treatment for acute
coronary thrombosis.13AfacilitatedPCI strategy involving full-
or half-dose adjunctive fibrinolytic therapy given before PCI
with stenting improves coronary flow acutely.14,15 However,
combination-facilitatedPCI involvingeither full-dose16orhalf-
dose lytic therapy17 causes paradoxical activation of throm-
bin, clot formation, and bleeding. Sezer et al15 modified this
strategy by administering adjunctive low-dose thrombolytic
therapywith250kUof streptokinaseat theendofprimaryPCI.
This approach appeared to improve myocardial reperfusion.
Since then, fibrin-specific fibrinolytic drugs and antithrom-
botic pharmacotherapy for STEMI have evolved.
T-TIME investigated whether a therapeutic strategy in-
volving low-dose intracoronary fibrinolytic therapy with al-
teplase infused early after coronary reperfusion would pre-
vent and reduce microvascular obstruction.
Methods
Trial Design
This was a randomized, double-blind, parallel-group phase 2
clinical trialof low-doseadjunctivealteplaseduringprimaryPCI.
Informed Consent and Study Protocol
Screening, witnessed verbal informed consent, study drug
administration, and acute assessments of efficacy took
place during the standard of care primary PCI. The protocol
and statistical analysis plan are provided in Supplements 1
and 2. The trial was reviewed and approved by an ethics
committee of the West of Scotland Research Ethics Service
(13-WS-0119), adhered to Guidelines for Good Clinical
Practice in Clinical Trials,18 and complied with the Declara-
tion of Helsinki.19
Participants and Eligibility Criteria
Patients with a clinical diagnosis of acute STEMI with persis-
tent ST-segment elevation or recent left bundle-branch block
with a symptom onset to reperfusion time of 6 hours or less
were potentially eligible for randomization. Radial artery ac-
cess was a requirement, and further angiographic criteria in-
cluded a proximal–mid coronary artery occlusion (TIMI coro-
nary flow grade 0 or 1) or, impaired coronary flow (TIMI flow
grade 2, slow but complete filling) in the presence of definite
angiographic evidence of thrombus (TIMI grade ≥2) in a ma-
jor coronary artery. Key exclusion criteria were a functional
coronary collateral supply (Rentrop grade ≥2) to the infarct-
related artery, any contraindication to fibrinolysis, and lackof
informed consent. The exclusion criteria are described in
Supplement 3.
Race/ethnicity was designated by the patient and re-
cordedby the local investigator to provide informationon the
participation of individuals with different ethnicity.
Setting
Theparticipantswereenrolled in11hospitals in theUnitedKing-
dom and guideline-based medical and invasive management
was recommended.3 Enrollment started onMarch 17, 2016.
Randomization, Implementation, and Blinding
Participants were randomized by staff in the catheter labora-
tory using an interactive voice response–based randomiza-
tion system.The randomization sequencewas computer gen-
erated, using the method of randomized permuted blocks of
length 6, with stratification by location of STEMI (anterior vs
nonanterior) and study site (Figure). The allocation sequence
was on a 1:1:1 basis between the placebo and alteplase (10mg,
20 mg) groups and the sequence was concealed electroni-
cally. The participants, staff, and researchers were blinded to
the treatment group allocation.
Standard Care
Primary PCI followed contemporary practice guidelines3
(Supplement 3).
Interventions
After successful reperfusion (TIMI flow grade ≥2), the partici-
pants received the allocated intervention immediately in the
catheter laboratory. The studydrug (placebo, alteplase 10mg,
or alteplase 20 mg) was manually infused before implanting
Key Points
Question In patients undergoing primary percutaneous coronary
intervention for acute ST-segment elevationmyocardial infarction
(STEMI), does adjunctive fibrinolytic therapy with low-dose
intracoronary alteplase given after reperfusion and before stent
implant reducemicrovascular obstruction?
Findings In this randomized clinical trial that included 440
participants randomized to receive alteplase 20mg, alteplase
10mg, or placebo, the primary analysis demonstrated that the
amount of microvascular obstruction (% left ventricular mass)
revealed bymagnetic resonance imaging was 3.5% in the alteplase
20-mg group and 2.3% in the placebo group, a difference that was
not statistically significant.
Meaning Adjunctive low-dose intracoronary alteplase given early
during primary percutaneous coronary intervention for acute
ST-segment elevationmyocardial infarction did not reduce
microvascular obstruction.
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the stent.Thedrugwas reconstitutedby theclinical staff using
20mL of sterile water for injection. The cardiologist then in-
fused the solubilized drug over 5 to 10 minutes directly into
the infarct-related artery proximal to the culprit lesion using
either an intracoronary catheter or the guiding catheter if se-
lectively engaged.
Outcomes
Themethods for the assessments of the primary and second-
ary outcomes are described in Supplement 3.
Primary Outcome
The primary outcome was the amount of microvascular ob-
struction (% of left ventricular mass) demonstrated by late
gadolinium-enhancedmagnetic resonance image (MRI) 10 to
15minutesafter administrationof contrastmedia.CardiacMRI
at 1.5 Twas scheduled during the index hospitalization, from
days 2 through 7 after enrollment.
Secondary Outcomes
Magnetic resonance imagingsecondaryoutcomes includedmi-
crovascular obstruction (presence/absence),myocardial hem-
orrhage (presence/absence), and the amount of myocardial
hemorrhageexpressedas apercentageof left ventricularmass
onMRI fromdays 2 through 7. Infarct size expressed as a per-
centageof left ventricularmass,myocardial salvage index, left
ventricular end–diastolic volume, left ventricular end–
systolic volume, and left ventricular ejection fractionwereob-
tained on days 2 through 7 and at 3 months.
Angiographicmeasuresof reperfusion (TIMIcoronary flow
grade,TIMImyocardialperfusiongrade,TIMI framecount)and
TIMI thrombus grade at the end of PCI were predefined sec-
ondary outcomes.
The percentage ST-segment resolution on an electrocar-
diogram (ECG) obtained 60 minutes after reperfusion vs be-
fore reperfusion and final infarct size revealed by the Selves-
ter QRS score at 3 months were also calculated.
TroponinTareaunder thecurve (AUC)wasmeasured from
blood samples obtained immediately before reperfusion (0
hours) and then again at 2 hours and at 24 hours. N-terminal
pro-brainnatriureticpeptide (NT-proBNP)wasmeasured from
days 2 through 7 and at 3 months after reperfusion, sched-
uled at the time of MRI.
Health Status
Health-related quality of life (HRQoL; EuroQol 5-Dimensions
3-Level [EQ-5D-3L]) was recorded from days 2 through 7 and
3 months after the MI. The EQ-5D is a standardized instru-
ment used as a measure of health outcome, made up of the
following 2 components: first, the health utility score, a
descriptive system comprising 5 dimensions—mobility, self-
care, usual activities, pain or discomfort, and anxiety or
depression; scores for each are combined to give a maximum
value of 1. Second, the visual analog scale reports the
patient’s self-rated health on a visual analog scale from 0
(worst imaginable) to 100 (best health imaginable).
Bleeding and Coagulation
Fibrinogen and other parameters of coagulation and hemo-
stasis servedas surrogatemeasuresofbleeding risk.20,21These
parameters weremeasured in blood samples when site logis-
tics permitted blood sample collection. The sampling time
Figure. Patient Recruitment, Randomization, and Flow Through T-TIME Study
1087 Excluded
838 Lack of inclusion criteria
15 Unable to undergo MRI
155 Other reasons
61 Logistical reasons
18 Declined participation
144 Randomized to receive 10 mg
of alteplase 
140 Received intervention
as randomized
4 Did not receive intervention
as randomized
3 Received no intervention
1 Received the incorrect dose
13 Did not undergo 2-7 d
cardiac MRIb
145 Randomized to receive 20 mg
of alteplase 
144 Received intervention
as randomized
1 Did not receive intervention
as randomized
1 Could not complete cardiac MRI
132 Attempted 3-mo cardiac MRI
131 Included in the primary analysis
2 Could not complete cardiac MRI
131 Attempted 3-mo cardiac MRI
129 Included in the primary analysis
1 Could not complete cardiac MRI
137 Attempted 3-mo cardiac MRI
136 Included in the primary analysis
13 Did not undergo 2-7 d
cardiac MRIb
14 Did not undergo 2-7 d
cardiac MRIb
440 Randomizeda
1527 Patients with acute ST-elevation
myocardial infarction were
assessed for eligibility
151 Randomized to receive placebo
150 Received intervention
as randomized
2 Did not receive intervention
as randomized
1 Received no intervention
1 Received the incorrect dose
Two patients (1 randomized to
placebo and 1 randomized to 10-mg
alteplase) received 20-mg alteplase
because an incorrect treatment pack
had been selected. MRI indicates
magnetic resonance imaging.
a All patients randomized were
considered part of the study
protocol, but those without a
comparative cardiac MRI were not
included in the primary analysis.
bOver the course of the study,
3 patients died in the 20-mg
alteplase group, 3 died in the
10-mg alteplase group, and 1 died
in the placebo group.
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pointswere at baselinebefore reperfusion (0hours) and2, and
24 hours after reperfusion. The parameters included fibrino-
gen and plasminogen (bothmeasures of coagulation and sys-
temic fibrinolysis), fibrin D-dimer (a measure of fibrin lysis),
tissue plasminogen activator (a measure of endogenous tis-
sue plasminogen activator and any circulating alteplase), and
prothrombin fragment1+2 (ameasure of thrombin activation).
Adverse Events
The adverse events and their definitions are listed in Supple-
ment 3. A major adverse cardiovascular event (MACE) was
defined as cardiovascular death, nonfatal myocardial infarc-
tion, or unplanned hospitalization for heart failure. Acute
cerebrovascular and systemic bleeds were defined using the
Bleeding Academic Research Consortium (BARC) criteria.22
All of these events were adjudicated by a clinical event com-
mittee who were independent of the trial and blinded to the
treatment allocation. Longer-term follow-up of health out-
comes (12 months, 3 years) blind to treatment group assign-
ment is ongoing.
Trial Coordination
An independent data and safetymonitoring committee and a
trial steering committee coordinated the trial and communi-
cated with the sponsor.
Sample Size and Statistical Methods
The target sample size was 618, based on obtaining 186 per
groupwhohadundergone anMRIwithin days 2 through 7 af-
ter enrollment, allowing for approximately 10%missingdata.
Thiswasdesigned togive90%powerata5%significance level,
to detect a difference between 2 groups of 1.72%, assuming a
mean (SD) of 3.2% (5.1%) for the extent of microvascular ob-
struction in the comparator group. This calculationwasbased
on the amount ofmicrovascular obstructiondemonstrated in
thesubgroupofpatientsenrolled intotheMR-MIcohortstudy23
who fulfilled the enrollment criteria for T-TIME.
Efficacy analyseswere analyzed according to randomiza-
tion group, that is, in relation to randomized treatment allo-
cation regardless of treatment received. Safetydatawere ana-
lyzed in relation to treatment received.
The primary outcome (extent of microvascular obstruc-
tion on MRI within days 2 through 7, as % of left ventricular
mass) was compared between groups using a stratified Wil-
coxon test (van Elteren test), stratified by the location of the
MI. Ninety-five percent confidence intervals for between-
group differences in the mean extent of microvascular
obstruction were derived by bootstrap resampling (10000
replicates), stratified by location of the MI; percentile confi-
dence intervals are reported. The primary analysis was to
compare the 20-mg alteplase group with the placebo group;
if this was significant at a 5% level, then the 10-mg alteplase
group would be compared with the placebo group as a pri-
mary analysis. This hierarchical approach was used to pre-
serve the overall type I error rate at 5%. However, if the
20-mg vs placebo comparison was not significant, the 10-mg
vs placebo comparison would be considered a secondary
analysis. Primary and secondary outcomes were also ana-
lyzed using linear regression (continuous outcomes), logistic
regression (binary outcomes), or proportional odds logistic
regression (ordinal outcomes). All models were adjusted for
the location of the MI. In linear regression models for con-
tinuous outcome measures, data were transformed where
necessary, to improve model residual distributions, and were
further adjusted for the baseline value of the outcome (where
appropriate). For the primary outcome, a post hoc analysis
was performed with multiple imputation for the missing out-
comes. Regression models were used to assess treatment
effects within prespecified subgroups through the use of
treatment-by-subgroup interactions. Further details are pro-
vided in Supplement 3. All tests were 2-tailed and assessed at
the 5% significance level. Missing outcome data were not
imputed. Because of the potential for type I error in the
analyses of secondary end points, these end points should be
interpreted as exploratory. All statistical analyses were car-
ried out with R v3.2.4 (R Development Core Team 2015)
according to a prespecified statistical analysis plan.
Prespecified Futility Analysis
Thefunder, theEfficacyandMechanismEvaluation (EME)pro-
gramof theNational Institute for Health Research (NIHR), re-
quired an interim analysis for futility and specified the crite-
ria before the start of the trial. This analysiswas scheduled for
whenapproximately40%ofpatientshadbeenrandomizedand
followed up to 3 months. Considering the primary outcome,
each active treatment group was compared with the placebo
group, and if the conditional power for showing abenefit over
placebo based on the current trendwas less than 30%, then a
recommendation would be made to halt that group.
Results
On the recommendation of the data and safety monitoring
committee, recruitment was discontinued on December 21,
2017, because a prespecified futility criterion for efficacywas
met. Specifically, the conditional power for an analysis on the
primary efficacy outcome based on 40% of the randomized
population (n = 267)with follow-up to 3monthswas less than
30% in both treatment groups.
By that time, 1527 patients undergoing primary PCI for
acute STEMI had been screened (Figure) and 440 patients
(mean age, 60.5 years; 15% women) had been randomized
(151 placebo, 144 alteplase 10 mg, and 145 alteplase 20 mg)
(Table 1). Seventeen patients (3.9%)withdrew from the study
during follow-up. All the other participants were followed up
for 3months. The final follow-up tookplace onApril 12, 2018.
Study Intervention
The standard of care procedure and study intervention are il-
lustrated inSupplement3andsummarized inTable2. Adjunc-
tive study drug therapy was administered to 435 patients
(98.9%); 5 patients did not receive any drug (Figure). Twopa-
tients (1 randomized to placebo and 1 randomized to 10-mg
alteplase) received20-mgalteplasebecausean incorrect treat-
ment pack had been selected.
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Table 1. Baseline Clinical and Treatment Characteristics of the Randomized Participants (N = 440)
Baseline Characteristics
No. (%) of Patients
Placebo
(n = 151)
Alteplase, 10 mg
(n = 144)
Alteplase, 20 mg
(n = 145)
Demographics
Age, mean (SD), y 60.7 (11.0) 59.6 (10.3) 61.2 (9.7)
Men 127 (84.1) 124 (86.1) 123 (84.8)
Women 24 (15.9) 20 (13.9) 22 (15.2)
White 143 (94.7) 134 (93.1) 136 (93.8)
Asian 7 (4.6) 9 (6.3) 8 (5.5)
BMI, mean (SD) 28.4 (5.3) 28.5 (4.8) 27.8 (4.4)
Presenting characteristics,
mean (SD)
Heart rate, beat/min 73.3 (22.5) 71.8 (15.9) 73.5 (17.6)
Systolic blood pressure, mm Hg 132 (26) 135 (25) 134 (25)
Diastolic blood pressure, mm Hg 79 (17) 80 (15) 81 (15)
Infarct location
Anterior 65 (43.0) 62 (43.1) 64 (44.1)
Inferior 70 (46.4) 67 (46.5) 70 (48.3)
Lateral 1 (0.7) 2 (1.4) 0
Posterior 14 (9.3) 11 (7.6) 8 (5.5)
Other 1 (0.7) 2 (1.4) 3 (2.1)
Medical history
Hypertensiona 47 (31.1) 45 (31.2) 49 (33.8)
Renal impairmentb 2 (1.3) 3 (2.1) 1 (0.7)
Diabetes mellitusa,c 19 (12.6) 19 (13.2) 18 (12.4)
Hypercholesterolemiaa 42 (27.8) 28 (19.4) 32 (22.1)
Smokinga
Current 75 (49.7) 72 (50.0) 62 (42.8)
Former (stopped >3 mo) 27 (17.9) 22 (15.3) 35 (24.1)
Never 49 (32.5) 50 (34.7) 48 (33.1)
Percutaneous coronary intervention 8 (5.3) 5 (3.5) 7 (4.8)
Angina 6 (4.0) 7 (4.9) 4 (2.8)
Myocardial infarction 6 (4.0) 6 (4.2) 8 (5.5)
Stroke or transient ischemic attacka 2 (1.3) 1 (0.7) 2 (1.4)
Peripheral vascular diseasea 3 (2.0) 3 (2.1) 6 (4.1)
Preexisting maintenance medication
Aspirin 27 (17.9) 17 (11.8) 22 (15.2)
P2Y12 inhibitor
Clopidogrel 1 (0.7) 0 (0.0) 1 (0.7)
Ticagrelor or prasugrel 9 (6.0) 4 (2.8) 7 (4.8)
Statin 40 (26.5) 29 (20.1) 28 (19.3)
β-Blocker 17 (11.3) 15 (10.4) 10 (6.9)
ACE inhibitor or ARB 23 (15.2) 28 (19.5) 27 (18.6)
Mineralocorticoid receptor
antagonist
1 (0.7) 2 (1.4) 1 (0.7)
Symptom onset to arrival
at primary PCI center,
median (IQR), h:min
2:05 (1:34-3:01) 2:11 (1:31-3:26) 2:15 (1:32-3:15)
Arrival at primary PCI center
to reperfusion,
median (IQR), min
24 (19-35) 23 (19-37) 25 (19-34)
Symptom onset to reperfusion,
median (IQR) h:min
2:36 (2:03-3:36) 2:50 (1:55-4:06) 2:44 (2:01-3:49)
Initial blood results on admission
Hemoglobin, mean (SD), g/dL 14.4 (1.4) 14.6 (1.2) 14.7 (1.3)
Platelet count, mean (SD), ×103/μL 253.7 (59.8) 267.9 (72.0) 260.4 (53.3)
Creatinine, mean (SD), μmol/L 80 (18) 80 (17) 80 (18)
Troponin T, median (IQR), ng/mL 0.06 (0.03-0.13) 0.06 (0.03-0.10) 0.06 (0.03-0.12)
Abbreviations: ACE, angiotensin-
converting enzyme;
ARB, angiotensin-receptor
blocker; BMI, bodymass index,
calculated as weight in kilograms
divided by height in meters
squared; IQR, interquartile range;
PCI, percutaneous coronary
intervention.
SI conversion factor: To convert
creatinine from μmol/L to mg/dL,
divide by 88.4.
a At least 1 risk factor for coronary
artery disease was required
for eligibility.
bRenal impairment was defined
according to the estimated
glomerular filtration rate (eGFR),
with an eGFR <59mL/min/1.73 m2
fulfilling the criteria for renal
impairment.
c Diabetes mellitus was defined
as a history of diet-controlled
or treated diabetes.
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Table 2. Procedure Characteristics and Outcomesa
Characteristics
No. (%) of Patients Who Underwent Cardiac MRIb
Placebo (n = 137)c Alteplase, 10 mg (n = 131)c Alteplase, 20 mg (n = 132)c
Infarct-related artery
Left anterior descending coronary 61 (44.5) 61 (46.6) 60 (45.5)
Circumflex 18 (13.1) 15 (11.5) 13 (9.8)
Right 58 (42.3) 55 (42.0) 59 (44.7)
Infarct artery diameter, mean (SD), mm 3.2 (0.4) 3.2 (0.5) 3.2 (0.4)
Mode of reperfusion
Aspiration thrombectomy 37 (27.0) 42 (32.3) 40 (30.3)
Balloon angioplasty 100 (73.0) 88 (67.7) 91 (68.9)
Primary stent 0 (0.0) 0 (0.0) 1 (0.8)
Balloon angioplasty prestent deployment 129 (94.2) 126 (96.2) 125 (94.7)
PCI with stent implant 136/137 (99.3) 128/130 (98.5) 130/131 (99.2)
Total No. of stents deployed
0 1 (0.7) 2 (1.4) 1 (0.8)
1 92 (67.2) 88 (67.2) 99 (75.0)
2 40 (29.2) 28 (21.4) 28 (21.2)
≥3 4 (2.9) 10 (7.6) 4 (3.0)
Total length of stents deployed, mean (SD), mm [n = 396] 33.5 (13.8) 35.7 (15.3) 32.0 (14.0)
Poststent dilatation 119 (86.9) 116 (88.5) 115 (87.1)
TIMI flow grade at initial angiographyd
0 (no flow) 117 (85.4) 103 (78.6) 103 (78.0)
1 (minimal flow) 3 (2.2) 13 (9.9) 14 (10.6)
2 or 3 (2, slow but complete, 3, normal flow) 17 (12.4) 15 (11.5) 15 (11.4)
TIMI thrombus grade at initial angiographye
0-2 (0, no thrombus, 2, definite, <½ vessel diameter) 0 (0.0) 0 (0.0) 0
3 (3, definite, >½ but <2 vessel diameters) 4 (2.6) 2 (1.5) 5 (3.8)
4 (definite thrombus ≥2 vessel diameters) 17 (12.4) 25 (19.1) 24 (18.2)
5 (total occlusion) 116 (84.7) 104 (79.4) 103 (78.0)
Acute therapy following the first medical contact
Aspirin 119 (86.9) 118 (90.1) 112 (84.8)
Loading dose of aspirin, No./total (%), mg
300 114/119 (95.4) 113/118 (95.8) 109/112 (97.3)
>300 5/119 (4.2) 5/118 (4.2) 3/112 (2.7)
Additional antiplatelet medication
None 15 (10.9) 10 (7.6) 17 (12.9)
Clopidogrel 43 (31.4) 48 (36.6) 51 (38.6)
Ticagrelor 76 (55.5) 68 (51.9) 60 (45.5)
Prasugrel 3 (2.2) 5 (3.8) 4 (3.0)
Unfractionated heparin, median (IQR), U 10 000 (7000-12 250) 10 000 (7500-13 000) 10 000 (7000-13 000)
Inhaled oxygen, No./total (%) 21/134 (15.5) 22/127 (17.3) 13/129 (10.1)
Intravenous morphine 93 (67.9) 100 (76.3) 104 (78.8)
Intravenous or intracoronary glycoprotein IIb/IIIa antagonist,
No./total (%)
13/134 (9.7) 27/127 (21.3) 21/129 (16.3)
Study drug treatment
Drug administered 137 (100.0) 129 (98.5) 132 (100.0)
Study drug given according to protocol, No./total (%) 136/137 (99.3) 127/129 (98.4) 131/132 (99.2)
Duration of study drug infusion, mean (SD), min 6.4 (1.9) 6.6 (2.0) 6.6 (2.0)
Abbreviations: IQR, interquartile range; PCI, percutaneous coronary
intervention; TIMI, Thrombolysis in Myocardial Infarction grade.
a The angiographic parameters are based on central laboratory assessments.
None of the patients received intravenous or intracoronary treatment with
bivalirudin, metoprolol, nicorandil, or sodium nitroprusside.
bUnless otherwise noted.
c Unless otherwise stated.
dTIMI flow grade is a visual assessment of antegrade coronary artery flow at
angiography, graded from0 (no flow) to 3 (normal flow).
e TIMI thrombus grade allows the classification of thrombus burden (greatest
dimension) revealed during coronary angiography.
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Primary and Secondary Outcomes
Magnetic resonance imaging was performed in 400 patients
(90.9%) fromdays 2 through 7 after enrollment and in 367pa-
tients (83.4%) at 3 months. The primary end point was avail-
able from396patients,meaning therewasmissingdata for the
primary endpoint in 10%.Themedian time toMRIwas4days
(interquartile range [IQR], 3-6 days ); for placebo, 4 days (IQR,
3-5 days); for 10-mg alteplase, 5 days (IQR, 3-6 days); and for
20-mgalteplase,4days (IQR,3-6days).Themedianfromreper-
fusion to the 3-month MRI were 91 days (IQR, 86-97 days).
Microvascular obstruction was demonstrated in 176 patients
(44.4%), and the amount of microvascular obstruction, ex-
pressed as the mean percentage of left ventricular mass, was
2.80%. Two clinical case examples are illustrated in eFig-
ure 2 in Supplement 3.
Primary Outcome
In theprimary analysis, the amountofmicrovascular obstruc-
tion revealed by MRI did not differ between the 20-mg al-
teplase group and the placebo group (mean, 3.5%vs 2.3%; es-
timated difference, 1.16%; 95% CI, −0.08% to 2.41%;
van Elteren test, P = .32). The comparison of the 10-mg al-
teplase group and the placebo group then became secondary
(mean, 2.6% vs 2.3%; estimated difference, 0.29%; 95% CI,
−0.76% to 1.35%; vanElteren test,P = .74;Table 3). Similar re-
sults were obtained using a linear regression model; with no
evidence of a difference in the primary outcome between all
patients randomized toalteplaseand those randomized topla-
cebo,meandifferenceonsquare root scale,0.15 (95%CI, −0.12
to 0.42; P = .28).
Aposthocanalysis of theprimaryoutcome includingmul-
tiple imputation for themissing valueswasperformed,which
produced similar results to the primary analysis.
Treatment effect differences on the primary outcome be-
tween prespecified subgroups defined by baseline character-
isticswere assessed.None of the interaction testswere statis-
tically significant (Table 3 and Table 4 and eTable 3 in
Supplement 3). In the subgroupofpatients presenting atmore
than4hours, theestimatedmeandifference in the square root
of theamountofmicrovascularobstructionbetweenthe20-mg
alteplasegroup (n = 27) and theplacebogroup (n = 26)was 1.12
(95% CI, 0.42-1.82; P = .002); however, the test for interac-
tion was not statistically significant (P = .06), so this sub-
group finding should not be interpreted as different from the
overall effect.
Secondary Outcomes
The AUC for troponin Tmeasured at baseline and at 2 and 24
hours after reperfusion among 317 patients was increased in
both treatment groups compared with placebo (eTable 4 in
Supplement 3; relative difference, 1.53; 95% CI, 1.16-2.01;
P = .002) for both alteplase groups combinedvsplacebo). The
troponinTAUCwas35%higher inpatients treatedwith20mg
of alteplase vs placebo (relative ratio, 1.53; 95% CI, 1.12-2.11;
P = .008).
Health-related quality of life scores were not signifi-
cantly different between the groups at 3 months. The EQ-5D
healthutility scoreswere0.88 inboth the20-mgalteplase and
placebo groups (mean difference, −0.002; 95% CI, −0.04 to
0.04; P = .93; Table 5).
Adverse Events
Compared with placebo, there was a dose-related increase in
the systemic concentrations of fibrin D-dimer and prothrom-
bin F1 + 2, and a slight reduction in plasminogen, in the al-
teplase groups (eTable 5 in Supplement 3). The systemic con-
centrations of fibrinogen and hemoglobin were numerically
similar between the groups.
Clinical Events
The adverse events are described in eTable 7 in Supple-
ment 3. MACE occurred in 15 patients (10.1%) in the placebo
group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%)
in the 20-mg alteplase group. Two patients experienced a
Table 3. Primary Outcome for Efficacy Analyses
Outcome
Primary Outcome Analyzed, mean (SD)a Between-Group Comparison
Placebo Alteplase 20 mg vs Placebo 10 mg vs Placebob
10 mg
(n = 129)
20 mg
(n = 131) % (95% CI) P Value % (95% CI) P Value
Primary outcomec
Microvascular obstruction
at 2-7 d, mean (SD),
% left ventricular mass
2.3 (4.3) 2.6 (4.5) 3.5 (5.8) 1.16
(−0.08 to 2.41)
.32d 0.29
(−0.76 to 1.35)
.74d
IQR 0.0 to 3.2 0.0 to 3.8 0.0 to 4.8
Range 0 to 28.8 0 to 27.0 0 to 26.1
Secondary analysis
Square root of microvascular
obstruction, at 2-7 d
0.23
(−0.09 to 0.55)
.15e 0.07
(−0.25 to 0.39)
.68e
Abbreviation: IQR, interquartile range.
a Unless otherwise indicated.
bGiven the 20-mg alteplase vs placebo comparison was not significant,
the 10-mg alteplase vs placebo comparison became a secondary
analysis.
c Given the high proportion of patients with a 0 value for microvascular
obstruction amount (55% of patients), the median value for microvascular
obstruction was 0 for all groups, while themean (SDs) are not ideal summaries
for these data. It has been reported as such for this reason.
dBetween-group comparison P values were derived from the stratified
Wilcoxon (van Elteren) test. This method does not automatically generate
confidence intervals. These were derived by bootstrap resampling (10000
replicates), stratified by the location of myocardial infarction.
e Between-group comparison P values derived from linear regressionmodel.
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stroke. Aspiration thrombectomy was used in 1 of these pa-
tientswhodevelopedahomonynoushemianopiaafter thepro-
cedure. Major bleeds were uncommon, occurring in 1 patient
in each of the 10-mg and 20-mg alteplase groups.
Discussion
Among patients with acute STEMI presenting within 6 hours
of symptom onset, adjunctive low-dose intracoronary al-
teplase given during the primary PCI compared with placebo
did not reduce microvascular obstruction.
This trial has several strengths. Comparable in scale with
other pivotal trials involving cardiac MRI,24 including the
INFUSE-AMI 4 and AIDA STEMI24,25 trials, the trial design se-
lectedpatientswithpresentingcharacteristics that increase in-
farct size, eg, proximal occlusion of a thrombus-laden coro-
naryartery.Mean infarct size (27%of leftventricularmass)was
almost 2-fold larger than that observed inanunselectedpopu-
lation of patients with STEMI.5,6 By limiting eligibility to an
Table 4. Primary Outcome for Prespecified Analyses
Primary Outcome Analyzed, Mean (SD)a Between-Group Comparison
P Value
for Interactiond
No. (%)
of Patients
Placebo
(n = 136)
Alteplase 20 mg vs Placebo 10 mg vs Placebob
10 mg
(n = 129)
20 mg
(n = 131) % (95% CI) P Valuec % (95% CI) P Valuec
Ischemic time, h
<2 98 (24.7) 1.4 (2.7) 1.5 (2.7) 2.7 (5.0) 0.25
(−0.43 to 0.92)
.48 0.09
(−0.55 to 0.73)
.78
.09
2-4 215 (54.3) 3.0 (5.0) 3.1 (5.3) 3.2 (5.7) −0.06
(−0.47 to 0.35)
.79 −0.01
(−0.45 to 0.42)
.95
>4 83 (21.0) 1.1 (2.6) 3.1 (4.6) 5.2 (6.9) 1.12
(0.42 to 1.82)
.002 0.53
(−0.15 to 1.22)
.13
Sex
Men 338 (85.4) 2.4 (4.5) 2.8 (4.6) 4.0 (6.2) 0.34
(0.00 to 0.68)
.05 0.11
(−0.23 to 0.45)
.51
.27
Women 58 (14.6) 1.8 (2.8) 1.7 (4.0) 0.8 (1.6) −0.39
(−1.20 to 0.43)
.35 −0.22
(−1.06 to 0.61)
.60
Age, y
<55 113 (28.5) 1.8 (2.9) 3.2 (5.2) 3.1 (4.7) 0.21
(−0.42 to 0.85)
.51 0.34
(−0.22 to 0.91)
.23
.68
55-65 168 (42.4) 3.0 (5.6) 2.3 (3.8) 3.6 (6.4) 0.14
(−0.35 to 0.63)
.58 −0.19
(−0.71 to 0.33)
.47
>65 115 (29.0) 2.1 (3.8) 2.5 (4.5) 3.5 (5.5) 0.33
(−0.25 to 0.91)
.27 0.10
(−0.50 to 0.69)
.75
MI location
Anterior 178 (44.9) 3.4 (5.6) 2.8 (4.0) 4.7 (6.9) 0.26
(−0.21 to 0.74)
.28 −0.08
(−0.55 to 0.39)
.74
.57
Nonanterior 221 (55.1) 1.5 (2.7) 2.5 (4.8) 2.5 (4.6) 0.20
(−0.22 to 0.63)
.35 0.19
(−0.24 to 0.62)
.38
Smoking status
Never 137 (34.6) 2.4 (4.0) 1.9 (3.7) 4.7 (7.5) 0.36
(−0.18 to 0.90)
.19 −0.25
(−0.79 to 0.30)
.38
.22
Former 74 (18.7) 1.3 (3.4) 1.8 (2.9) 3.2 (5.7) 0.57
(−0.12 to 1.27)
.10 0.28
(−0.52 to 1.07)
.50
Current 185 (46.7) 2.6 (4.8) 3.3 (5.2) 2.6 (3.8) 0.00
(−0.48 to 0.47)
.99 0.19
(−0.26 to 0.64)
.41
Initial TIMI coronary
flow grade
0 (none) 320 (80.8) 2.6 (4.5) 3.1 (4.9) 3.9 (6.2) 0.21
(−0.13 to 0.56)
.23 0.06
(−0.28 to 0.41)
.73
.71
1 (minimal) 30 (7.6) 0.0 (0.0) 1.4 (2.3) 3.5 (4.8) 1.37
(−0.24 to 2.98)
.10 0.87
(−0.76 to 2.50)
.29
≥2 (2, slow but complete
to 3, normal flow)
46 (11.6) 0.7 (2.9) 0.5 (1.0) 0.8 (2.9) 0.07
(−0.83 to 0.97)
.88 0.06
(−0.86 to 0.97)
.90
Preexisting antiplatelet
medication
Yes 58 (14.6) 2.4 (3.5) 1.4 (4.0) 3.9 (6.3) 0.31
(−0.48 to 1.11)
.44 −0.46
(−1.32 to 0.40)
.30
.31
No 338 (85.4) 2.3 (4.5) 2.8 (4.5) 3.4 (5.8) 0.22
(−0.13 to 0.56)
.22 0.14
(−0.20 to 0.49)
Abbreviations: MI, myocardial infarction; TIMI, Thrombolysis in Myocardial
Infarction grade.
a Unless otherwise indicated.
bGiven the 20-mg alteplase vs placebo comparison was not significant, the
10-mg alteplase vs placebo comparison became a secondary analysis.
c Between-group comparison P values are derived from linear regression
model.
d Interaction test P values reported from regressionmodels with treatment
included as a 3-level categorical variable.
Adjunctive Alteplase During Primary PCI in Patients With Acute MI Original Investigation Research
jama.com (Reprinted) JAMA January 1/8, 2019 Volume 321, Number 1 63
© 2019 American Medical Association. All rights reserved.
Downloaded From:  by a University of Leeds User  on 01/22/2019
Table 5. Secondary Outcomes for Efficacy and Health Outcomes
Outcome
No. of
Patients
Treatment Groupa Between-Group Comparison
Placebo
(n = 151)
Alteplase 20 mg vs Placebo
P Value
10 mg vs Placebo
P Value
10 mg
(n = 144)
20 mg
(n = 145) % (95% CI) % (95% CI)
Coronary Angiogram
TIMI flow grade after PCI
0 (no flow) 0 (0.0) 1 (0.7) 1 (0.7) 0.73
(0.41 to 1.29)
.28b 0.83
(0.46 to 1.49)
.52b
1 (minimal flow) 6 (4.0) 6 (4.2) 3 (2.1)
2 (slow but complete) 20 (13.2) 22 (15.3) 29 (20.0)
3 (normal flow) 125 (82.8) 115 (79.9) 112 (77.2)
TIMI myocardial perfusion
grade after PCIc
0 (no blush) 46 (30.5) 62 (43.1) 49 (33.8) 0.93
(0.61 to 1.41)
.73b 0.70
(0.46 to 1.08)
.11b
1 (incomplete clearance) 11 (7.3) 2 (1.4) 9 (6.2)
2 (persistent) 51 (33.8) 48 (33.3) 49 (33.8)
3 (normal blush
and clearance)
43 (28.5) 32 (22.2) 38 (26.2)
Corrected TIMI frame
count after PCId
438 20 (14 to 27) 20 (15 to 28) 22 (14 to 30) 1.07
(0.94 to 1.23)
.31e 1.10
(0.96 to 1.25)
.19e
TIMI thrombus
grade after PCI
0 (no thrombus) 147 (97.4) 137 (95.1) 141 (97.2) 1.04
(0.25 to 4.23)
.96f 1.87
(0.53 to 6.53)
.33f
1 (possible thrombus) 2 (1.3) 4 (2.8) 3 (2.1)
2 (definite,
<½ vessel diameter)
1 (0.7) 2 (1.4) 0 (0.0)
3 (definite, >½
but <2 vessel diameters)
0 (0.0) 0 (0.0) 0 (0.0)
4 (definite,
>2 vessel diameters)
1 (0.7) 0 (0.0) 0 (0.0)
5 (occluded artery) 0 (0.0) 1 (0.7) 1 (0.7)
Electrocardiogram (acute)
ST-segment resolution
60 min, mean (SD), %
396 49.6 (38.9) 43.7 (45.0) 44.2 (46.0) −5.0
(−15.1 to 5.2)
.34e −5.8
(−16.2 to 4.6)
.27e
Biochemistry (Acute), Mean (SD)
Troponin T, AUC 317 2.80 (1.10 to 5.32) 2.94 (1.57 to 5.98) 3.80 (1.56 to 6.63) 1.53
(1.12 to 2.11)
.008e 1.52
(1.10 to 2.09)
.01e
NT-proBNP in 2-7 d,
pg/mL
394 784 (386 to 1350) 849 (417 to 1586) 791 (412 to 1355) 1.00
(0.78 to 1.27)
.98e 1.12
(0.88 to 1.42)
.35e
Cardiac MRI (2-7 d)
Microvascular
obstruction, No. (%)
396 59/136 (43.4) 58/129 (45.0) 59/131 (45.0) 1.07
(0.66 to 1.73)
.80f 1.06
(0.65 to 1.73)
.81f
Myocardial
hemorrhage, No. (%)
378 52/128 (40.6) 54/121 (44.6) 56/129 (43.4) 1.12
(0.68 to 1.84)
.65f 1.17
(0.71 to 1.94)
.54f
Myocardial hemorrhage,
mean (SD), % left
ventricular mass,
360 1.56 (3.78) 1.98 (3.68) 2.45 (4.80) 0.86
(−0.17 to 1.88)
.10e 0.36
(−0.69 to 1.41)
.50e
Infarct size, mean (SD),
% left ventricular mass
396 26.3 (13.7) 27.3 (12.4) 26.6 (13.4) 0.23
(−2.64 to 3.11)
.87e 0.80
(−2.08 to 3.69)
.58e
Extent of myocardial
edema, mean (SD),
% left ventricular mass
397 40.4 (11.4) 41.9 (11.4) 41.0 (11.5) 0.44
(−1.72 to 2.60)
.69e 1.17
(−0.99 to 3.33)
.29e
Myocardial salvage
index, mean (SD)
396 0.37 (0.25) 0.36 (0.23) 0.36 (0.24) −0.01
(−0.07 to 0.05)
.68e −0.01
(−0.07 to 0.04)
.64e
Left ventricular
end-diastolic volume,
median (IQR), mL
400 166 (144 to 195) 177 (157 to 208) 166 (143 to 195) 1.00
(0.95 to 1.05)
.94e 1.06
(1.01 to 1.12)
.02e
Left ventricular
end-systolic volume,
median (IQR), mL
400 90 (77 to 112) 96 (80 to 124) 95 (79 to 110) 1.00
(0.94 to 1.08)
.93e 1.08
(1.01 to 1.16)
.03e
Left ventricular
ejection fraction,
mean (SD), %
400 44.5 (8.8) 43.6 (8.1) 44.2 (8.4) −0.27
(−2.16 to 1.63)
.78e −0.76
(−2.66 to 1.14)
.44e
(continued)
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ischemic time of 6 or fewer hours, the aimwas to include par-
ticipants with salvageable myocardium. Alteplase was used
within its licensed indication and at doses that are available
in the clinic. Bias was minimized through a double-blind de-
sign and use of core laboratory analyses. The increase in sys-
temic concentrations of fibrin D-dimers without any change
infibrinogenindicates that fibrinolysisor fibringenerationwere
localized to the heart.
The potential for harm with facilitated PCI was high-
lighted in the ASSENT-4 (Assessment of the Safety and Effi-
cacy of a New Treatment Strategy with Percutaneous Coro-
nary Intervention 4)16 and FINESSE (Facilitated Intervention
with Enhanced Reperfusion Speed to Stop Events)17 trials. In
ASSENT-4,16 compared with primary PCI (standard care),
full-dose tenecteplase combined with PCI was associated
with an increase in the primary end point of death, conges-
tive heart failure, or shock within 90 days. Ischemic cardiac
complications and ischemic stroke were also increased in the
intervention group. Despite more initial patency in the
infarct-related artery, residual thrombus burden was higher
Table 5. Secondary Outcomes for Efficacy and Health Outcomes (continued)
Outcome
No. of
Patients
Treatment Groupa Between-Group Comparison
Placebo
(n = 151)
Alteplase 20 mg vs Placebo
P Value
10 mg vs Placebo
P Value
10 mg
(n = 144)
20 mg
(n = 145) % (95% CI) % (95% CI)
Electrocardiogram (3 mo)
Final infarct size
(Selvester score),
mean (SD)g
368 10.3 (9.0) 12.1 (10.6) 12.1 (9.9) 1.70
(−0.64 to 4.03)
.15e 1.69
(−0.69 to 4.08)
.16e
Biochemistry (3 mo)
NT-proBNP, pg/mL 372 228 (94 to 521) 260 (100 to 442) 239 (119 to 528) 0.99
(0.76 to 1.28)
.93e 0.98
(0.75 to 1.27)
.88e
Ratio of NT-proBNP
at 3 mo, d 2-7
354 0.32 (0.20 to 0.58) 0.33 (0.18 to 0.51) 0.34 (0.22 to 0.49) 0.95
(0.79 to 1.15)
.63e 8.69
(−316.94 to 334.32)
.45e
Cardiac MRI (3 mo)
Infarct size,
mean (SD), % left
ventricular mass
364 18.7 (12.5) 18.5 (11.2) 19.3 (12.2) 0.79
(−2.00 to 3.58)
.58e −0.21
(−3.02 to 2.61)
.89e
Myocardial
salvage index,
mean (SD)h
358 0.56 (0.24) 0.58 (0.21) 0.55 (0.23) −0.02
(−0.08 to 0.04)
.52e 0.01
(−0.05 to 0.07)
.67e
Left ventricular
end-diastolic volume,
median (IQR), mL
367 164
(144-192)
173
(152-206)
170
(142-195)
1.00
(0.94 to 1.06)
.87e 1.06
(1.00 to 1.12)
.06e
Left ventricular
end-systolic volume,
median (IQR), mL
367 79
(64-103)
88
(71-110)
88
(67-108)
1.03
(0.94 to 1.12)
.57e 1.08
(0.99 to 1.18)
.09e
Left ventricular
ejection fraction,
mean (SD), %
367 49.8 (8.8) 48.5 (8.0) 48.6 (8.5) −1.25
(−3.30 to 0.80)
.23e −1.30
(−3.38 to 0.77)
.22e
Health-Related Quality of Life at 3 mo, Mean (SD)
EQ-5D health
utility scorei
391 0.88 (0.16) 0.89 (0.15) 0.88 (0.16) −0.002
(−0.04 to 0.04)
.93e 0.008
(−0.03 to 0.05)
.68e
Change from
baseline
378 0.07 (0.17) 0.08 (0.23) 0.06 (0.18) −0.005
(−0.05 to 0.04)
.83e 0.014
(−0.03 to 0.06)
.55e
EQ-5D visual
analogi
396 78.0 (17.5) 79.8 (15.2) 81.8 (15.1) 3.89
(0.07 to 7.71)
.05e 1.89
(−1.97 to 5.75)
.34e
Change from
baseline
392 5.6 (19.9) 8.2 (17.2) 6.7 (18.4) 1.0
(−3.45 to 5.59)
.66e 2.50
(−2.00 to 7.01)
.28e
Abbreviations: EQ-5D, EuroQol 5-dimension scale; MRI, magnetic resonance
imaging; NTproBNP, N-terminal probrain natriuretic peptide; PCI, percutaneous
coronary intervention; TIMI, Thrombolysis in Myocardial Infarction grade.
a Unless otherwise indicated.
bBetween-group comparison P values derived from proportional odds logistic
regressionmodel.
c TIMI myocardial perfusion grade provides a score for ground-glass appearance
“blush” of contrast entering themicrovasculature and contrast washout.
dCorrected TIMI frame count is an objective continuous variable index of
coronary blood flow, representing the time (in cine frames) for contrast to
reach a standardized landmark, corrected for vessel length (normal value,
<27 frames).
e Between-group comparison P values derived from linear regressionmodel.
f Between-group comparison P values derived from a logistic regression
model.
g Selvester score translates subtle changes in ventricular depolarization on the
electrocardiogram to a surrogate measure of infarct size; there is a maximum
score of 32 points with 1 point corresponding to 3% of the left ventricle.
hMyocardial salvage index is calculated by subtracting the infarct size from the
extent of myocardial edema (represents jeopardizedmyocardium) and then
indexing by dividing by the extent of myocardial edema, values range from0
(no salvage) to 1 (complete salvage).
i EQ-5D is a standardized instrument used as a measure of health outcome,
made up of 2 components: (1) the health utility score, a descriptive system
comprised of 5 dimensions: mobility, self-care, usual activities, pain or
discomfort, and anxiety or depression. Scores for each are combined to give a
maximum value of 1; (2) the visual analog scale reports the patient’s self-rated
health on a visual analog scale from 0 (worst imaginable) to 100 (best health
imaginable). Baseline health status was assessed using the EQ-5D, which was
completed by patients at the time of their 2- to 7-day follow-up visit. Each
patient had 1 blood sample available for each time point. Data summarized as
mean (SD) or median (interquartile range) for normal and nonnormally
distributed data, respectively.
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in the facilitated PCI group and tissue reperfusion and clini-
cal outcomes were worse.26 These results may be explained
by comparatively inadequate anticoagulation and, poten-
tially, formation of fibrin and thrombus in the group treated
with tenecteplase.26,27 The importance of effective antico-
agulation to mitigate the prothrombotic effects of fibrinolytic
therapy with alteplase has been reported previously.27
The targeted, intracoronary infusionof the studydrugwas
intended to minimize the systemic release of alteplase and
minimize bleeding events. Alteplase was selected because it
is a fibrin-specific fibrinolyticdrugwithabrief circulatinghalf-
life ( ≈ 5minutes). In order to further reduce the possibility of
harmful remote bleeds, patientswith risk factors for bleeding
were excludedand thePCIprocedureswereperformedvia the
radial artery. The rates of bleeding eventswerewithin the ex-
pected range for primary PCI.28
The increase in troponinT in thealteplasegroupsmaypro-
videmechanistic insights. The troponinTAUC isdistinct from
the othermeasures of infarct size thatwere obtained at single
time points. An alternative explanation such as biomarker
washout after fibrinolysismay explain why this rise in tropo-
nin was not associated with an increase in MRI measures of
infarction. The dose-related increase in the systemic concen-
trations of fibrin D-dimer indicates that clot lysis had oc-
curred. An increase in prothrombin F1 + 2 concentrations was
observed in the alteplase groups, despite achieving therapeu-
tic anticoagulation with unfractionated heparin. The unde-
siredprocoagulanteffectof fibrinolytic therapythroughthrom-
bin activation27 may have led to microvascular thrombosis,
limiting the efficacy of the intervention.
Contemporary practice guidelines call for more research
to identify new treatments for microvascular obstruction.3
There is growing interest in the potential efficacy of ad-
junctive intracoronary fibrinolytic therapy during pri-
mary PCI. Two phase 3 trials are investigating the efficacy
of reduced doses of either alteplase (STRIVE, NCT03335839)
or tenecteplase (RESTORE-MI; ACTRN12618000778280)
(Supplement 3).
Limitations
The study had several limitations. First, the study presents
short-term findings up to 3months. Second, the trial was dis-
continuedwhenprespecified futility criteriaweremet.The in-
terim analysis and related stopping criteria had been re-
quiredandspecifiedby the funder.Theobjectivesof thisphase
2 trial included evidence synthesis for mechanisms evalua-
tion as well as efficacy. To an extent, premature discontinua-
tion limits themechanisms evaluation. Third, because of the
largenumberof secondaryendpointsandthepotential for type
I error, all of these findings should be interpreted as only ex-
ploratory. Fourth, study drug administration was focused at
a single time point before stent implantwhen coronary blood
flow was variable. Alternatively, in the STRIVE and
RESTORE-MI trials, the intervention is scheduled at the end
of primary PCI, after stent implant.
Conclusions
Among patients with acute STEMI presenting within 6 hours
of symptoms, adjunctive low-dose intracoronary alteplase
given during the primary percutaneous intervention com-
pared with placebo did not reduce microvascular obstruc-
tion. The study findings do not support this treatment.
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